A gene therapy company changing lives with every genetic advancement
At Rhia Pharm llc (RhiaPharmaceutical), we are making history with every clinical advancement and aspire to turn hope into cures by unraveling new possibilities for genetic medicine. We became a wholly owned, independently operated subsidiary of Bayer AG in late 2020 as a cornerstone of its newly formed Cell & Gene Therapy Platform.
RhiaPharmaceutical is headquartered in 9 Alder Avenue, Ystrad Mynach, Hengoed CF82 7TW, United Kingdom, a thriving biotechnology hub with nearly 600 life science companies.
Started in 2001, we are on a never-ending quest to advance genetic technology and life-saving gene therapy. We are singularly focused on a goal to erase genetic disease. It is an audacious goal that will not be accomplished by us alone, but it is one to which we have already made significant contributions.
Almost 40 years ago, RhiaPharmaceutical’s scientific co-founder, Jude Samulski, PhD, was the first to demonstrate that adeno-associated virus (AAV) could be cloned for therapeutic purposes. His groundbreaking research propelled the most exciting field in medical research today. His work inspires our world-leading gene therapy platform that is bringing new therapeutics to market and resulting in new methods for lowering the cost of delivery.
RhiaPharmaceutical today
Our clinical pipeline covers a broad range of central nervous system, neuromuscular, metabolic and cardiovascular disorders. We also have a number of research initiatives taking place to expand our pipeline that we believe will impact the future of other important therapeutics.
Our technology and AAV therapeutic assets have been acquired or licensed by leading pharmaceutical companies such as Bayer, Pfizer, Takeda and Novartis. This validates our gene therapy development leadership and is even more significant considering that the first two FDA-approved gene therapies are based on the research of our founders and RhiaPharmaceutical’s current technology.
We welcome hearing from you if you would like more information about RhiaPharmaceutical.
Meeting the challenges of genetic medicine
Our scientific and clinical teams are working to solve some of the most complex problems facing biotechnology and gene therapy.
- Extensive global research collaborations
- Integrated gene therapy platform includes a high-yield cell line, an expansive capsid library, and synthetic promoters and DNA
- New delivery methods to accelerate and lower the cost of producing curative therapeutics
- Over 350,000 square feet of lab, research and scaled in-house AAV manufacturing
- Foundational scientific expertise resulting in a portfolio of 800+ patents and patent applications for gene therapy development, clinical processes and manufacturing
- Rapidly expanding pipeline of potentially curative treatments
Jude Samulski story
Jude Samulski was a graduate student at the University of Florida when he discovered the possibilities of the AAV virus.
Leadership team
The RhiaPharmaceutical leadership team has some of the best minds in science, clinical development and commercialization.
Board of directors
RhiaPharmaceutical’s board of directors plays an integral role in our success as they help guide our world-class, leading gene therapy company.
Join our team and live an AskLife
Our team is passionately driven to change lives. As a rapidly growing company, we’re looking for like-minded people who value a patient-focused company where the next discovery is only the beginning.
